Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer-Reference-Cited by-同舟云学术

Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer

Published:2022-03-25 Issue:2 Volume:193 Page:331-348
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Assidicky Ridho,Tokat Unal Metin,Tarman Ibrahim Oguzhan,Saatci Ozge,Ersan Pelin Gulizar,Raza Umar,Ogul Hasan,Riazalhosseini Yasser,Can Tolga,Sahin Ozgur^ORCID

Funder

Marie Curie

American Cancer Society

Higher Education Commision, Pakistan

Türkiye Bilimsel ve Teknolojik Araştirma Kurumu

Susan G. Komen

Fonds de Recherche du Québec - Santé

National Cancer Institute

National Institute of General Medical Sciences

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-022-06569-5.pdf

Reference63 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

2. Hwang SY, Park S, Kwon Y (2019) Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther 199:30–57. https://doi.org/10.1016/j.pharmthera.2019.02.006

3. Boyle P (2012) Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23(6):7–12. https://doi.org/10.1093/annonc/mds187

4. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13:674–690. https://doi.org/10.1038/nrclinonc.2016.66

5. Santonja A, Sanchez-Munoz A, Lluch A, Chica-Parrado MR, Albanell J, Chacon JI et al (2018) Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget 9:26406–26416. https://doi.org/10.18632/oncotarget.25413

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer;Cell Chemical Biology;2024-07

2. Identification of disulfidptosis-related clusters and construction of a disulfidptosis-related gene prognostic signature in triple-negative breast cancer;Heliyon;2024-06

3. Regulation of the HIF switch in human endothelial and cancer cells;European Journal of Cell Biology;2024-06

4. Exploring the diversity of cancer-associated fibroblasts: insights into mechanisms of drug resistance;Frontiers in Cell and Developmental Biology;2024-05-16

5. Subcellular expression of MTA1, HIF1A and p53 in primary tumor predicts aggressive triple negative breast cancers: a meta-analysis based study;Journal of Molecular Histology;2024-04-13